Gliknik Inc. develops biologic immunotherapies targeting cancer and autoimmune diseases. Its lead clinical program is biropepimut-S, an immuno-oncology compound in a randomized double-blind, placebo-controlled phase 2 study nearing completion assessing two-year prevention-of-recurrence endpoints in high-risk squamous cell oral cavity cancer. GL-2045 is a recombinant mimetic of pooled human IVIG being developed by Gliknik's licensee Pfizer as a potential alternative to address IVIG shortages in autoimmune diseases. GL-0719 is a novel complement modulator poised to enter a phase 1 trial in 2021, and the company maintains additional preclinical programs. Financially, Gliknik has completed an $11.5 million Series C and has secured $81 million in total funding to date. The company intends to use the new capital to advance its clinical and preclinical pipeline from its Baltimore operations. Gliknik is a biopharmaceutical company based in the University of Maryland BioPark. The company develops new therapies for patients with cancer and immune disorders. According to SEC filings cited in the article, Gliknik raised $2.8 million in equity. The article does not provide details on investors, prior rounds, or operating metrics such as revenue or user figures. Future plans and leadership information were not specified in the article. Gliknik's focus on cancer and immune‑disorder therapeutics places it squarely in early-stage biopharma development. Gliknik is a biopharmaceutical company that creates new therapies for patients with cancer and immune disorders. The company is based in the University of Maryland BioPark. According to SEC filings, Gliknik has been raising capital and has an offering described in filings. The filings show the company has raised $9.8 million in equity as part of an offered $15 million. No operating metrics, investors, or past financing rounds are listed in the article. Additional strategic or product details beyond its therapeutic focus were not provided in the coverage. Gliknik is a Baltimore, MD-based biopharmaceutical company focused on therapies for cancer and immune/inflammatory disorders. Its lead program is an IVIG-mimetic compound, GL-2045, which the company plans to advance toward the clinic. The company intends to study GL-2045 in autoimmune conditions, initially Myasthenia gravis, and a variety of other neurological indications. Gliknik also has clinical immunomodulator compounds currently in multiple-dose studies in patients with advanced cancers, including multiple myeloma and head and neck cancers. The recently raised capital will be used to further advance GL-2045 and its clinical programs. The company was founded in 2007 and is led by CEO David S. Block. Gliknik develops biopharmaceutical therapies for cancer and immune disorders based on its stradomer™ platform. Its lead recombinant candidate, GL-2045, is in preclinical development and has shown efficacy in animal models of inflammation and autoimmunity. The company intends to use recently raised funds to initiate a clinical program in autoimmune diseases for GL-2045. Gliknik raised $3.5M in equity financing to support this work, with existing investor Joel B. Braunstein participating in the round. Founded in 2007 and led by President and CEO David S. Block, the company is based in Baltimore, MD. No operating metrics or prior financing rounds were disclosed in the article.

Total raised

$33M

Funding rounds

5

Latest round

Series C

Latest activity

Jun 2021